Get the Stockscreener App
2.24
12.56%
0.25
Allurion Technologies Inc stock is traded at $2.24, with a volume of 158.04K.
It is up +12.56% in the last 24 hours and down -31.29% over the past month.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
See More
Previous Close:
$1.99
Open:
$2.09
24h Volume:
158.04K
Relative Volume:
0.93
Market Cap:
$16.71M
Revenue:
$34.75M
Net Income/Loss:
$-24.76M
P/E Ratio:
-0.1867
EPS:
-12
Net Cash Flow:
$-50.91M
1W Performance:
-6.67%
1M Performance:
-31.29%
6M Performance:
-36.90%
1Y Performance:
-86.00%
1-Day Range:
$2.0075
$2.24
1-Week Range:
$1.98
$2.46
52-Week Range:
$1.98
$22.25
Allurion Technologies Inc Stock (ALUR) Company Profile
Name
Allurion Technologies Inc
Sector
Industry
Phone
508-647-4000
Address
11 HURON DR STE 200, NATICK
Compare ALUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALUR
Allurion Technologies Inc
|
2.24 | 17.67M | 34.75M | -24.76M | -50.91M | -12.00 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Allurion Technologies Inc Stock (ALUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-02-24 | Initiated | TD Cowen | Buy |
| Sep-06-24 | Initiated | ROTH MKM | Buy |
| Feb-09-24 | Initiated | Jefferies | Buy |
Allurion Technologies Inc Stock (ALUR) Latest News
Allurion Technologies, Inc. (ALUR) reports Q2 loss, misses revenue estimates - FXStreet
Allurion Technologies, Inc. (ALUR) Reports Q2 Loss, Misses Revenue Estimates - sharewise.com
Allurion Technologies to implement reverse stock split - MSN
Allurion Technologies: Navigating Short-Term Turbulence for Long-Term Growth in Obesity Care - AInvest
Allurion Technologies Q2 Earnings Miss Estimates, Shares Down 78% - AInvest
ALLURION TECHNOLOGIES, INC. SEC 10-Q Report - TradingView
Will Allurion Technologies Inc. stock hit new highs in YEAR2025 Growth vs Value & Low Risk Investment Opportunities - mustnews.co.kr
Is Allurion Technologies Inc. Equity Warrant stock trending bullishPrice Action & Long Hold Capital Preservation Plans - newsyoung.net
Does Allurion Technologies Inc. have declining or rising EPSJuly 2025 Intraday Action & Real-Time Market Trend Scan - newsyoung.net
Allurion Technologies Inc. Breaks Below Key Support Level2025 Market Outlook & AI Powered Market Trend Analysis - newsimpact.co.kr
Allurion Technologies Delays Q2 2025 Financial Filing - The Globe and Mail
Is Allurion Technologies Inc. Equity Warrant exposed to political riskMarket Risk Report & Weekly Market Pulse Alerts - thegnnews.com
Allurion Revenue Drops 71 Percent in Q2 - AOL.com
Drawdown in Allurion Technologies Inc. Equity Warrant May Be Nearing End2025 Trade Ideas & Daily Volume Surge Signals - 선데이타임즈
Allurion Technologies Reports Q2 Results and Strategic Pivot - MSN
Allurion Technologies reports Q2 revenue $3.38M, consensus $6.2M - MSN
Allurion Technologies Inc. (NYSE:ALUR) Q2 2025 Earnings Call Transcript - MSN
Why Allurion Technologies Inc. stock attracts strong analyst attentionQuarterly Profit Review & Reliable Entry Point Alerts - newsyoung.net
Allurion Technologies stock rating reiterated at Buy by TD Cowen - Investing.com Canada
Is Allurion Technologies Inc. Forming a Bottom PatternWeekly Trend Report & Community Verified Swing Trade Signals - newsyoung.net
Allurion pivots to combination therapy strategy while pursuing U.S. market launch - MSN
Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Allurion Technologies Shifts Strategy Amid Q2 Earnings - TipRanks
Allurion Technologies shares rise 1.17% after-hours after reporting Q2 2025 financial results and announcing new strategic direction. - AInvest
Allurion Technologies shares fall 1.94% intraday after reporting Q2 2025 financial results and strategic updates. - AInvest
Allurion Technologies' Q2 2025: Unpacking Contradictions in Strategy, Cash Runway, and Market Execution - AInvest
Allurion Technologies Q2 Revenue Drops 71% Amid Strategic Pivot and Cost Cuts - AInvest
Earnings call transcript: Allurion Technologies Q2 2025 sees strategy shift - Investing.com
Earnings call transcript: Allurion Technologies Q2 2025 sees strategy shift By Investing.com - Investing.com Canada
Allurion Technologies Q2 Earnings: Revenue Down 71.2% YoY, Operating Expenses Decline 48% - AInvest
Published on: 2025-08-10 16:00:24 - metal.it
Allurion WRT ALUR.WS 2025Q2 Earnings Preview Upside Potential on Innovative Product Launch - AInvest
Allurion Technologies Inc expected to post a loss of 78 cents a shareEarnings Preview - TradingView
Allurion Technologies Announces Strategic Restructuring Plan - The Globe and Mail
Allurion Technologies shares rise 2.90% premarket after announcing a strategic restructuring plan. - AInvest
Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025 - BioSpace
Press Release: Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025 - 富途牛牛
Allurion Sets Q2 2025 Earnings Call: Key Financial Updates Coming August 13 - Stock Titan
Allurion Technologies Inc on August 5, Co announced strategic restructuring plan which includes reduction in workforce by 65%SEC filing - MarketScreener
Allurion Technologies shares rise 2.53% premarket after announcing new strategic direction with focus on low-dose GLP-1 combination therapy. - AInvest
Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry - BioSpace
Allurion Unveils GLP-1 Combo Strategy: Targets Muscle Mass Preservation in Weight Loss | ALUR Stock News - Stock Titan
Allurion Technologies shares fall 3.83% intraday after announcing new strategic direction with focus on low-dose GLP-1 combination therapy. - AInvest
Should I hold or sell Allurion Technologies Inc. stock in 2025Build wealth steadily with proven investment strategies - Jammu Links News
What institutional investors are buying Allurion Technologies Inc. Equity Warrant stockBuild a winning portfolio with smart picks - Jammu Links News
Is it the right time to buy Allurion Technologies Inc. Equity Warrant stockAccess high-quality stock research instantly - Jammu Links News
How does Allurion Technologies Inc. compare to its industry peersExplosive market performance - Jammu Links News
Is Allurion Technologies Inc. stock overvalued or undervaluedBuild a balanced portfolio for long-term success - Jammu Links News
How does Allurion Technologies Inc. Equity Warrant compare to its industry peersInvest confidently with advanced analysis tools - Jammu Links News
What are the technical indicators suggesting about Allurion Technologies Inc. Equity WarrantBuild wealth with professional market analysis - Jammu Links News
What makes Allurion Technologies Inc. stock price move sharplyGet real-time updates on market movers - Jammu Links News
Allurion Technologies Inc Stock (ALUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):